{"filing":{"accession_number":"0001193125-26-263831","cik":"0001680367","ticker":"STTK","company_name":"Shattuck Labs, Inc.","form":"8-K","filing_date":"2026-06-09","report_date":null,"primary_document":"d120796d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312526263831/d120796d8k.htm"},"events":[{"id":5925,"run_id":5198,"accession_number":"0001193125-26-263831","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.73,"summary":"Shattuck Labs announced Phase 1 clinical trial data for its lead DR3 blocking antibody SL-325, demonstrating favorable safety, tolerability, and pharmacokinetic results with low immunogenicity (3.7% ADA rate). The company outlined material clinical milestones including initiation of Phase 2b trial (RECEPTIVE-CD1) in Q3 2026 and an IND filing for SL-846 in H1 2027, while simultaneously raising approximately $54.9 million in gross proceeds through warrant exercises (96% of outstanding warrants from August 2025 private placement).","company_name":"Shattuck Labs, Inc.","ticker":"STTK","filing_date":"2026-06-09","form":"8-K","submitted_at":null,"items":[{"id":5558,"accession_number":"0001193125-26-263831","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces Phase 1 clinical trial data for SL-325 (lead DR3 blocking antibody) and outlines material clinical milestones including initiation of a Phase 2b trial (RECEPTIVE-CD1) in Q3 2026 and an IND filing for SL-846 in H1 2027. While this is clinical/development progress rather than a financial event, earnings release, or other specifically enumerated category, the announcement of Phase 1 data and near-term Phase 2b initiation would materially affect investor assessment of a clinical-stage biotech company's pipeline advancement and probability of success.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:30:12.784797+00:00","company_name":"","ticker":null,"filing_date":""},{"id":5559,"accession_number":"0001193125-26-263831","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The filing discloses two distinct material events: (1) Phase 1 clinical trial data for SL-325 showing favorable safety, tolerability, and pharmacokinetic results with low immunogenicity (3.7% ADA rate), and (2) warrant exercises generating approximately $54.9 million in gross proceeds (96% of outstanding warrants from the August 2025 private placement). While the clinical data is significant for a biotech company's pipeline, it does not fit neatly into \"earnings_release\" (no financial results) or other specific categories. The warrant exercise is a capital-raising event but does not constitute a dilutive issuance in the traditional sense (these are exercises of previously issued warrants, not new equity issuance). Together, these events are material to investor assessment of the company's clinical progress and financial position, but the mixed nature of the disclosure—clinical progress plus warrant capital raise—makes \"other_material\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:30:12.784797+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5558,"accession_number":"0001193125-26-263831","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces Phase 1 clinical trial data for SL-325 (lead DR3 blocking antibody) and outlines material clinical milestones including initiation of a Phase 2b trial (RECEPTIVE-CD1) in Q3 2026 and an IND filing for SL-846 in H1 2027. While this is clinical/development progress rather than a financial event, earnings release, or other specifically enumerated category, the announcement of Phase 1 data and near-term Phase 2b initiation would materially affect investor assessment of a clinical-stage biotech company's pipeline advancement and probability of success.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:30:12.784797+00:00","company_name":"Shattuck Labs, Inc.","ticker":"STTK","filing_date":"2026-06-09"},{"id":5559,"accession_number":"0001193125-26-263831","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The filing discloses two distinct material events: (1) Phase 1 clinical trial data for SL-325 showing favorable safety, tolerability, and pharmacokinetic results with low immunogenicity (3.7% ADA rate), and (2) warrant exercises generating approximately $54.9 million in gross proceeds (96% of outstanding warrants from the August 2025 private placement). While the clinical data is significant for a biotech company's pipeline, it does not fit neatly into \"earnings_release\" (no financial results) or other specific categories. The warrant exercise is a capital-raising event but does not constitute a dilutive issuance in the traditional sense (these are exercises of previously issued warrants, not new equity issuance). Together, these events are material to investor assessment of the company's clinical progress and financial position, but the mixed nature of the disclosure—clinical progress plus warrant capital raise—makes \"other_material\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:30:12.784797+00:00","company_name":"Shattuck Labs, Inc.","ticker":"STTK","filing_date":"2026-06-09"}]}